ÂÜÀòÂÒÂ×

Asish Xavier has extensive experience in venture investments, serving as Vice President at Johnson & Johnson Innovation - JJDC since June 2004, leading numerous high-profile investments in biotechnology and healthcare companies. Prior roles include Principal and Senior Associate within JJDC, where significant investments included Aquinox Pharmaceuticals and Ilypsa, the latter acquired by Amgen. Asish also holds board positions at several organizations, including Pipeline Therapeutics, SonoThera, Verana Health, Paige, and Legend Biotech, which completed its IPO in June 2020. With an MBA from The Wharton School and a Ph.D. in Chemical Engineering from the University of Houston, Asish's academic background complements a career focused on innovation and investment within the life sciences sector.